ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Jupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS)

0.8667
-0.1433
(-14.19%)
Closed February 08 4:00PM
0.8666
-0.0001
(-0.01%)
After Hours: 7:58PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.8666
Bid
0.8666
Ask
0.9099
Volume
643,393
0.83 Day's Range 1.06
0.8501 52 Week Range 19.51
Market Cap
Previous Close
1.01
Open
1.00
Last Trade Time
Financial Volume
$ 598,729
VWAP
0.930581
Average Volume (3m)
750,433
Shares Outstanding
33,103,860
Dividend Yield
-
PE Ratio
-5.88
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-4.78M

About Jupiter Neurosciences Inc

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we pri... Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL¿ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Jupiter Neurosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker JUNS. The last closing price for Jupiter Neurosciences was $1.01. Over the last year, Jupiter Neurosciences shares have traded in a share price range of $ 0.8501 to $ 19.51.

Jupiter Neurosciences currently has 33,103,860 shares outstanding. The market capitalization of Jupiter Neurosciences is $33.43 million. Jupiter Neurosciences has a price to earnings ratio (PE ratio) of -5.88.

JUNS Latest News

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2234-20.4954128441.091.13960.85016082441.02604058CS
4-7.8234-90.02761795178.699.350.850112068293.33125591CS
12-3.1334-78.335419.510.85017504335.51529642CS
26-3.1334-78.335419.510.85017504335.51529642CS
52-3.1334-78.335419.510.85017504335.51529642CS
156-3.1334-78.335419.510.85017504335.51529642CS
260-3.1334-78.335419.510.85017504335.51529642CS

JUNS - Frequently Asked Questions (FAQ)

What is the current Jupiter Neurosciences share price?
The current share price of Jupiter Neurosciences is $ 0.8666
How many Jupiter Neurosciences shares are in issue?
Jupiter Neurosciences has 33,103,860 shares in issue
What is the market cap of Jupiter Neurosciences?
The market capitalisation of Jupiter Neurosciences is USD 33.43M
What is the 1 year trading range for Jupiter Neurosciences share price?
Jupiter Neurosciences has traded in the range of $ 0.8501 to $ 19.51 during the past year
What is the PE ratio of Jupiter Neurosciences?
The price to earnings ratio of Jupiter Neurosciences is -5.88
What is the reporting currency for Jupiter Neurosciences?
Jupiter Neurosciences reports financial results in USD
What is the latest annual profit for Jupiter Neurosciences?
The latest annual profit of Jupiter Neurosciences is USD -4.78M
What is the registered address of Jupiter Neurosciences?
The registered address for Jupiter Neurosciences is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Jupiter Neurosciences website address?
The website address for Jupiter Neurosciences is www.jupiterneurosciences.com
Which industry sector does Jupiter Neurosciences operate in?
Jupiter Neurosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
$ 0.4191
(126.54%)
816.59M
CDTConduit Pharmaceuticals Inc
$ 2.831
(82.65%)
144.17M
GSIWGarden Stage Ltd
$ 0.79
(78.73%)
219.64M
TOIIWOncology Institute Inc
$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
$ 1.19
(54.55%)
84.73M
FTELFitell Corporation
$ 2.70
(-57.01%)
2.3M
SGBXSafe and Green Holdings Corporation
$ 0.6401
(-44.82%)
5.65M
NKLANikola Corporation
$ 0.4432
(-41.10%)
52.44M
PLRXPliant Therapeutics Inc
$ 7.785
(-34.85%)
6.44M
LIPOLipella Pharmaceuticals Inc
$ 3.08
(-33.76%)
2.2M
MGOLMGO Global Inc
$ 0.4191
(126.54%)
816.59M
RIMEAlgorhythm Holdings Inc
$ 0.0169
(-20.66%)
274.2M
NVDANVIDIA Corporation
$ 129.84
(0.90%)
228.2M
GSIWGarden Stage Ltd
$ 0.79
(78.73%)
219.64M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0537
(14.74%)
212.29M

JUNS Discussion

View Posts
tw0122 tw0122 2 months ago
Back down to $11 halt 38% 
👍️0
Invest-in-America Invest-in-America 2 months ago
JUNS: WHERE do you see that 120%??? Is that your price TARGET??? (Etrade, etc.,.shows only 38%.)
👍️0
tw0122 tw0122 2 months ago
$17 +120%
👍️0
Invest-in-America Invest-in-America 2 months ago
JUNS: O.K., sounds fine to me, Homeboy!!
👍️0
tw0122 tw0122 2 months ago
From Saturn off to Jupiter $11.79 + 50%
👍️0
Invest-in-America Invest-in-America 2 years ago
JUNS (IPO):
👍️0
makinezmoney makinezmoney 2 years ago
$JUNS: IPO is launching next week

We are waiting on it.



Jupiter Neurosciences, Inc. has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.

https://jupiterneurosciences.com/








GO $JUNS
👍️0
Invest-in-America Invest-in-America 2 years ago
JUNS: Evidently, now ready-to-go on E-Turd, Fidelity, etc.
👍️0
spindog spindog 3 years ago
Ticker hasn’t shown up on E*TRADE yet
👍️0
crudeoil24 crudeoil24 3 years ago
IPO scheduled for February 3, 2022.
👍️0
crudeoil24 crudeoil24 3 years ago
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
👍️0

Your Recent History

Delayed Upgrade Clock